These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6142449)

  • 21. Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial.
    Pamelia FX; Gheorghiade M; Beller GA; Bishop HL; Olukotun AY; Taylor CR; Watson DD; Grunwald AM; Sirowatka J; Carabello BA
    Am Heart J; 1983 Dec; 106(6):1369-76. PubMed ID: 6359846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response of pulmonary circulation to oral pirbuterol in chronic airflow obstruction.
    Peacock A; Busst C; Dawkins K; Denison DM
    Br Med J (Clin Res Ed); 1983 Oct; 287(6400):1178-80. PubMed ID: 6138119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of oral and inhaled salbutamol and oral pirbuterol on right and left ventricular function in chronic bronchitis.
    Winter RJ; Langford JA; Rudd RM
    Br Med J (Clin Res Ed); 1984 Mar; 288(6420):824-5. PubMed ID: 6142748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure.
    Awan NA; Evenson MK; Needham KE; Evans TO; Hermanovich J; Taylor CR; Amsterdam E; Mason DT
    Circulation; 1981 Jan; 63(1):96-101. PubMed ID: 7438412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential value of oral beta 2-adrenoceptor agonists in congestive heart failure: a haemodynamic and metabolic study.
    Timmis AD; Bergman G; Walker L; Monaghan MJ; Jewitt DE
    Int J Cardiol; 1984 Mar; 5(3):327-38. PubMed ID: 6706438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure.
    Canepa-Anson R; Dawson JR; Kuan P; Poole-Wilson PA; Sutton GC; Cockrill B; Reuben SR
    Br J Clin Pharmacol; 1987 Feb; 23(2):173-81. PubMed ID: 3828194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new beta-2 adrenoceptor agonist (pirbuterol) in the treatment of ischaemic heart failure.
    Nelson GI; Silke B; Barker MC; Saxton CA; Taylor SH
    Eur Heart J; 1982 Jun; 3(3):238-45. PubMed ID: 6125392
    [No Abstract]   [Full Text] [Related]  

  • 28. The use of two inhaled beta agonists for the treatment of COPD: a summary of European data.
    Holten K; Lulling J; Schaaning J; Vander Straeten M; Verstraeten JM
    J Asthma; 1993; 30(2):123-6. PubMed ID: 8096208
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease.
    Stålenheim G; Wegener T; Grettve L; Lundbäck B; Melander B; Osterman K; Piitulainen E; Zetterström O
    Respiration; 1994; 61(6):305-9. PubMed ID: 7824809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical use of inotropes in cardiac failure: dopamine, dobutamine, prenalterol and pirbuterol.
    Rae AP; Tweddel AC; Hutton I
    Herz; 1983 Feb; 8(1):23-33. PubMed ID: 6832690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term haemodynamic, pulmonary function and symptomatic effects of pirbuterol in COPD.
    Neilly JB; Carter R; Tweddel A; Martin W; Hutton I; Banham SW; Stevenson RD
    Respir Med; 1989 Jan; 83(1):59-65. PubMed ID: 2511610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
    Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
    Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New beta 2-adrenergic agonist aerosols.
    Kelly HW
    Clin Pharm; 1985; 4(4):393-403. PubMed ID: 2864159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pirbuterol, a selecttve beta2 adrenergic bronchodilator.
    Moore PF; Constantine JW; Barth WE
    J Pharmacol Exp Ther; 1978 Nov; 207(2):410-8. PubMed ID: 712629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol.
    Ence TJ; Tashkin DP; Ho D; Child JS
    Ann Allergy; 1979 Oct; 43(4):229-36. PubMed ID: 555600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonbronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease.
    Ashutosh K; Dev G; Steele D
    Chest; 1995 Jan; 107(1):173-8. PubMed ID: 7813271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative efficacy of prenalterol and pirbuterol for beta-1 adrenoceptors: measurement of agonist affinity by alteration of receptor number.
    Kenakin TP; Beek D
    J Pharmacol Exp Ther; 1984 May; 229(2):340-5. PubMed ID: 6143816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Inhalation therapy with selective beta 2-sympathomimetic drugs. Effect of pirbuterol administered via the Autohaler and salbutamol administered via the Diskhaler in obstructive respiratory tract disease].
    Hoffarth HP; Freyberger H; Völkl KP; Ulmer WT
    Fortschr Med; 1990 Mar; 108(8):162-4. PubMed ID: 2186991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists.
    Packer M
    J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S38-43. PubMed ID: 2478808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
    Berger WE; Noonan MJ
    J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.